A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

ALS-008176

ALS-008176 tablets

DRUG

Placebo

Identical placebo tablets

Trial Locations (21)

235

Taipei Med. Uni-Shuang Ho Hosp, New Taipei City

2145

Westmead Hospital, Northmead

3050

The Royal Melbourne Hospital, Parkville

3168

Monash Heal.-Monash Lung&Sleep, Clayton

4101

Mater Adult Hospital, South Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

4870

Cairns Hospital, Cairns

5011

The Queen Elizabeth Hospital, Woodville South

6021

Wellington Regional Hospital, Newtown

30033

Infectious Disease Specialists of Atlanta, Atlanta

32726

Lake Internal Med. Assoc., Eustis

33013

The Research Center, Inc., Hialeah

33186

JDH Medical Group LLC, Miami

33606

Tampa Genereal Hospital, Tampa

34952

St Lucie Medical Center, Port Saint Lucie

41701

Kentucky Lung Clinic, PSC, Hazard

48085

William Beaumont Hospital, Troy

49007

Bronson Methodist Hosp. Ped, Kalamazoo

63110

Washington Univ School of Med, St Louis

65212

University of Missouri- Clinical Research Center, Columbia

188770

Raffles Hospital, Singapore

Sponsors
All Listed Sponsors
lead

Alios Biopharma Inc.

INDUSTRY

NCT02673476 - A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus | Biotech Hunter | Biotech Hunter